The 3rd Annual Liquid Biopsies and Minimally-Invasive Diagnostics 2016 Conference brings together academic researchers, industry researchers, as well as biotechnology and pharmaceutical companies to explore the expanding and evolving field whereby Circulating Biomarkers of various classes are being evaluated for their potential to be developed into diagnostics for cancer as well as other disease classes.
This Liquid Biopsies Conference focuses primarily on biofluid-based molecular biomarkers, such as circulating tumor DNA (ctDNA) as well as circulating tumor cells (CTCs), and protein-based circulating biomarkers. There is much interest in the potential of ctDNA for developing biological fluid-based biopsies (such as using plasma, urine, or other biofluids) and the presenters in this track bring together the most up-to-date information and current state-of-the-field.
The conference further explores the potential of various minimally-invasive circulating biomarker classes, such as circulating-free DNA (cfDNA), CTCs, and Extracellular Vesicles (EVs), for development of novel diagnostics for patient monitoring and precision/targeted medicine.
Authors of best abstracts would be offered with the opportunity to publish their full articles in “Special Issue on Liquid Biopsy” of Cancer Translational Medicine Journal.
Call for Posters
You can also present your research on a poster while attending the meeting. Submit an abstract for consideration now!
Poster Submission Deadline: 16 September 2016
Sponsorship and Exhibition Opportunities
Jeff Fan, Exhibition Manager
Confirmed Speakers to date
Lyle Arnold, Chief Scientific Officer, Biocept